메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Fapon to Debut Shine mT8000 Open-Access, High Throughput Clinical Chemistry and Immunoassay Analyzer at ADLM 2025

CHICAGO, July 29, 2025 -- Fapon, a global leading life sciences company, will debut its Shine mT8000 Fully Automated Clinical Chemistry and Immunoassay System at the ADLM 2025 Annual Scientific Meeting. This launch marks a significant milestone in Fapon's commitment to building an open, intelligent, and high-efficiency diagnostic ecosystem that helps clinical laboratories to enhance efficiency for clinical chemistry and immunoassays. The Shine mT8000 system packs powerful performance into a footprint just 5 square meters, combining biochemistry and immunoassay capabilities in o
- 김갑성 기자
- 2025-07-29 18:00
WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication

[ 메디채널 김갑성 기자 ] Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats. Finished building will be one of the world's largest modular biologics Drug Product (DP) facilities, and will enhance WuXi Biologics' leadership in end-to-end DP capabilities. SINGAPORE, July 29, 2025 -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced construction has begun for a new modular Drug Product (DP) facility, wh
- 김갑성 기자
- 2025-07-29 16:00
Tigermed Completes Acquisition of Japanese CRO Micron

HANGZHOU, China and TOKYO, July 29, 2025 -- Tigermed (300347.SZ / 3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmaceutical and medical device products, today announces the completion of its acquisition of CRO company Micron,Inc. Founded in 2005 and headquartered in Tokyo, Micron is a Japan-based Contract Research Organization (CRO) focusing in medical imaging and clinical trial services with over 160 employees. Micron brings nearly two decades of expertise in clinical research and the largest team of imaging expert
- 김갑성 기자
- 2025-07-29 13:37
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Obtained Orphan Drug Designation from the U.S. FDA for the Treatment of GC/GEJ

SUZHOU, China, July 29, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and gastroesophageal junction cancer (GC/GEJ). GC/GEJ is the fifth most common cancer and the fifth leading cause of cancer death worldwide. According to the 2022 Global Cancer Statistics report released by the International Agency for Research on Cancer (IARC), a subsidiary of the World Health Organization, there
- 김갑성 기자
- 2025-07-29 10:37
Agilent and Nanyang Technological University's NEWRI Sign Agreement to Enhance Water Contaminant Research in Singapore

SINGAPORE, July 29, 2025 -- Agilent Technologies Inc. (NYSE: A) announced the recent signing of a Memorandum of Understanding (MOU) with the Nanyang Environment & Water Research Institute (NEWRI), outlining their collaboration in advancing environmental and water research over the next three years. NEWRI is a leading research institute at Nanyang Technological University, Singapore (NTU Singapore), ranked 13th globally for Environmental Sciences by QS World University Ranking in 2025¹. The collaboration aims to further strengthen Singapore's capabilities in detecting e
- 김갑성 기자
- 2025-07-29 09:00
FROM THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE

Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older adults at risk of cognitive decline. A structured intervention with more support and accountability showed greater improvement compared to a self-guided intervention. In a large, representative group of older adults at high risk for cognitive decline, multidomain lifestyle interventions were delivered with high adherence and safety. Cognitive benefits were consistent across age, sex, ethnicity, heart health status and apolipoprotein E-e4 genotype. TORONTO, July 29, 2025 -- The
- 김갑성 기자
- 2025-07-29 02:39
Siemens Healthineers Receives Frost & Sullivan's 2025 North America Company of the Year Award for Excellence in Advanced Visualization Applications

[ 메디채널 김갑성 기자 ] Recognized for delivering diagnostic innovation, workflow efficiency, and enterprise imaging leadership through advanced visualization solutions SAN ANTONIO, July 28, 2025 -- Frost & Sullivan is pleased to announce that Siemens Healthineers has been awarded the 2025 North America Company of the Year Recognition in the advanced visualization applications industry for its outstanding achievements in diagnostic innovation, seamless platform integration, and customer impact. This recognition underscores Siemens Healthineers' market leadership in transforming medical i
- 김갑성 기자
- 2025-07-28 22:00
XellSmart Completed World's First Patient Dosing in its Registrational Clinical trial for iPSC-derived Subtype-specific Neural Cell Therapy for Spinal Cord Injury

SUZHOU, China, July 28, 2025 -- XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved registrational clinical trial. This Phase I China registrational clinical trial for XS228 Cell Injection – the world's first "off-the-shelf", allogeneic, iPSC-derived, spinal neural progenitor cell therapy targeting major neurological disorders, specifically spinal cord injury (SCI) – has commenced. The clinical trial initiation meeting was held at The Third Affiliated Hospital of Sun Yat-sen Univer
- 김갑성 기자
- 2025-07-28 21:10
World's First Engineered Exosome for Hair Growth & Localized Fat Reduction Secure INCI Designation: ImmVira Accelerates Access to Billion-Dollar Aging-related Market

SUZHOU, China, July 28, 2025 -- ImmVira Group ("ImmVira" or the "Company")recently announced that its engineered exosome products MVR-EX104 ("EX104", for alopecia treatment) and MVR-EX105 ("EX105", for localized fat accumulation) have obtained International Nomenclature of Cosmetic Ingredients (INCI) designations following review by the International Cosmetic Ingredient Nomenclature Committee (INC). This dual milestone underscores ImmVira's breakthrough leadership in functional aesthetic ingredients, bring forward revolutionary consumer healthca
- 김갑성 기자
- 2025-07-28 20:28
Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC)

[ 메디채널 김갑성 기자 ] Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 -- Alamar Biosciences, a company pioneering precision proteomics to drive the earliest detection of disease, today announced the presentation of NULISA™ data in over 30 scientific sessions and poster presentations at the AAIC conference held July 27-31 in Toronto, Canada. The NULISA platform is poised to redefine the landscape of biomarker detection, offering unprecedented sensitivity, specificit
- 김갑성 기자
- 2025-07-28 20:12

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-09-01_MON

2025-08-31_SUN

2025-08-30_SAT

Global Trade Review Announces GTR Asia 2025 in Singapore - the premier platform for the trade community in the Asia Pacific region - hits over 1,500 registration for September 2-3 23:39

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 01일 09시 00분